NCT00121810View on ClinicalTrials.gov

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

305

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Kidney Transplantation
Interventions
DRUG

mycophenolate mofetil [CellCept]

1.0-1.5 g oral dose twice daily

DRUG

Corticosteroids

As prescribed

DRUG

Calcineurin inhibitors

As prescribed

DRUG

Sirolimus

As prescribed

Trial Locations (36)

10029

New York

10032

New York

19107

Philadelphia

21201

Baltimore

22908

Charlottesville

27710

Durham

29425

Charleston

30322

Atlanta

37232

Nashville

38104

Memphis

46202

Indianapolis

52242

Iowa City

57105

Sioux Falls

60153

Maywood

70112

New Orleans

75246

Dallas

77555

Galveston

78284

San Antonio

80262

Denver

90033

Los Angeles

90057

Los Angeles

92123

San Diego

92501

Riverside

93309

Bakersfield

94115

San Francisco

97201

Portland

94304-1509

Palo Alto

06106-3316

Hartford

20010-2975

Washington D.C.

46202-5124

Indianapolis

40536-0293

Lexington

02114-2696

Boston

48202-2689

Detroit

08103

Camden

07039

Livingston

45267-0558

Cincinnati

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00121810 - Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients | Biotech Hunter | Biotech Hunter